Merck & Co. has acquired worldwide rights to LaNova Medicines' cancer therapy LM-299 for $588 million, a bispecific immunotherapy targeting PD-1 and VEGF, currently in Phase 1 testing. This move comes as a response to increasing competition, particularly after ivonescimab outperformed Keytruda in a lung cancer trial. The deal could yield LaNova up to $2.7 billion based on development milestones, highlighting Merck's strategy to bolster its pipeline ahead of Keytruda's patent expiration in 2028.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.
